StockData
Corvus Pharmaceuticals, Inc. logo

Corvus Pharmaceuticals, Inc. (CRVS) stock

CRVSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$10.19+0.02 (+0.20%)

Close on Nov 18, 2026Market cap $857.19MP/E –Yield –

Corvus Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Corvus Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$56.96M. For fiscal 2025 it was -$42.97M. The highest annual figure on record is -$13.77M in fiscal 2015.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$42.97M–
FY2024Dec 31, 2024-$27.55M–
FY2023Dec 31, 2023-$23.41M–
FY2022Dec 31, 2022-$32.57M–
FY2021Dec 31, 2021-$38.63M–
FY2020Dec 31, 2020-$43.76M–
FY2019Dec 31, 2019-$48.85M–
FY2018Dec 31, 2018-$49.22M–
FY2017Dec 31, 2017-$56.52M–
FY2016Dec 31, 2016-$36.98M–
FY2015Dec 31, 2015-$13.77M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$19.30M–
Q1 FY2026Mar 31, 2026-$14.88M–
Q4 FY2025Dec 31, 2025-$12.22M–
Q3 FY2025Sep 30, 2025-$10.57M–
Q2 FY2025Jun 30, 2025-$10.26M–
Q1 FY2025Mar 31, 2025-$9.92M–
Q4 FY2024Dec 31, 2024-$8.11M–
Q3 FY2024Sep 30, 2024-$7.26M–
Q2 FY2024Jun 30, 2024-$5.94M–
Q1 FY2024Mar 31, 2024-$6.25M–
Q4 FY2023Dec 31, 2023-$5.65M–
Q3 FY2023Sep 30, 2023-$5.56M–
Q2 FY2023Jun 30, 2023-$5.62M–
Q1 FY2023Mar 31, 2023-$6.57M–
Q4 FY2022Dec 31, 2022-$5.67M–
Q3 FY2022Sep 30, 2022-$12.47M–
Q2 FY2022Jun 30, 2022-$7.01M–
Q1 FY2022Mar 31, 2022-$7.41M–
Q4 FY2021Dec 31, 2021-$6.81M–
Q3 FY2021Sep 30, 2021-$9.05M–
Q2 FY2021Jun 30, 2021-$11.29M–
Q1 FY2021Mar 31, 2021-$11.48M–
Q4 FY2020Dec 31, 2020-$9.88M–
Q3 FY2020Sep 30, 2020-$9.85M–
Q2 FY2020Jun 30, 2020-$10.77M–
Q1 FY2020Mar 31, 2020-$13.27M–
Q4 FY2019Dec 31, 2019-$11.44M–
Q3 FY2019Sep 30, 2019-$11.51M–
Q2 FY2019Jun 30, 2019-$13.60M–
Q1 FY2019Mar 31, 2019-$12.31M–
Q4 FY2018Dec 31, 2018-$11.17M–
Q3 FY2018Sep 30, 2018-$11.15M–
Q2 FY2018Jun 30, 2018-$12.26M–
Q1 FY2018Mar 31, 2018-$14.64M–
Q4 FY2017Dec 31, 2017-$12.19M–
Q3 FY2017Sep 30, 2017-$12.94M–
Q2 FY2017Jun 30, 2017-$15.17M–
Q1 FY2017Mar 31, 2017-$16.22M–
Q4 FY2016Dec 31, 2016-$11.25M–
Q3 FY2016Sep 30, 2016-$10.48M–

More Corvus Pharmaceuticals figures

See a number that looks wrong?